Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOIIW) Asset Writedowns and Impairment (2021 - 2023)

Oncology Institute posted quarterly Asset Writedowns and Impairment of $2.0 million for Q4 2023, up 2587.84% year-on-year from $74000.0 in Q4 2022, and up 5927.27% on a QoQ basis from $33000.0 in Q3 2023.

Oncology Institute (TOIIW) has 3 years of Asset Writedowns and Impairment data on file, last reported at $2.0 million in Q4 2023.

  • For the quarter ending Q4 2023, Asset Writedowns and Impairment rose 2587.84% year-over-year to $2.0 million; the trailing twelve-month figure through Sep 2024 stood at $2.0 million (up 1794.29% YoY), and the FY2023 full-year result was $2.0 million, up 324.37% from the prior year.
  • Asset Writedowns and Impairment for Q4 2023 stood at $2.0 million, up from $33000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $2.0 million in Q4 2023 and bottomed at -$722000.0 in Q2 2021.
  • The 3-year median for Asset Writedowns and Impairment is $74000.0 (2022), against an average of $189000.0.
  • Peak annual rise in Asset Writedowns and Impairment reached 2587.84% in 2023, while the deepest fall reached 102.86% in 2023.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $250000.0 in 2021, then tumbled by 70.4% to $74000.0 in 2022, then jumped by 2587.84% to $2.0 million in 2023.
  • The last three Asset Writedowns and Impairment figures came in at $2.0 million (Q4 2023), $33000.0 (Q3 2023), and -$3000.0 (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 HCA Healthcare 84.64 Bn 87.02 Bn 16.26 Bn
2 Tenet Healthcare 15.22 Bn 14.39 Bn 4.41 Bn
3 Davita 13.10 Bn 13.96 Bn 1.07 Bn
4 Encompass Health 10.50 Bn 11.12 Bn 1.34 Bn
5 Ensign 9.69 Bn 9.09 Bn 293.37 Mn
6 Universal Health Services 8.92 Bn 8.88 Bn 3.21 Bn
7 Fresenius Medical Care AG 7.31 Bn 4.93 Bn 22,843.10 Bn
8 Chemed 5.83 Bn 5.81 Bn 215.76 Mn
9 Pacs 5.76 Bn 5.51 Bn 345.96 Mn
10 Oncology Institute - - 139.16 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 1.99 Mn
Dec 31, 2023 1.99 Mn
Sep 30, 2023 33,000.00
Sep 30, 2023 33,000.00
Jun 30, 2023 -3,000.00
Jun 30, 2023 -3,000.00
Mar 31, 2023 1,000.00
Mar 31, 2023 1,000.00
Dec 31, 2022 74,000.00
Dec 31, 2022 74,000.00
Sep 30, 2022 143,000.00
Sep 30, 2022 143,000.00
Jun 30, 2022 105,000.00
Jun 30, 2022 105,000.00
Mar 31, 2022 154,000.00
Mar 31, 2022 154,000.00
Dec 31, 2021 250,000.00
Dec 31, 2021 250,000.00
Sep 30, 2021 55,000.00
Sep 30, 2021 55,000.00
Jun 30, 2021 -722,000.00
Jun 30, 2021 -722,000.00